Stay updated on GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe record history now shows the latest site revision, v3.6.5, added to the log. The prior revision, v3.6.4, is removed from the log.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedThe footer revision label updated from v3.6.3 to v3.6.4, indicating a small version update to the page. The change is cosmetic and does not modify the study records or functionality.SummaryDifference0.1%

- Check50 days agoChange DetectedA new revision entry, Revision: v3.6.3, was added to the record history, replacing the previous v3.6.2. This updates the page's revision metadata without altering the study data.SummaryDifference0.1%

- Check58 days agoChange DetectedA new history entry (Version 35) with a Study Status update and revision v3.6.2 was added to the study record on 2026-06-24, and the older revision v3.6.0 was removed on 2026-06-10.SummaryDifference0.3%

- Check72 days agoChange DetectedRecruitment status updated to No longer looking for participants, indicating enrollment has closed for this study. This update is logged under Revision: v3.6.0 on 2026-06-10.SummaryDifference1%

- Check79 days agoChange DetectedThe history page displays a new site revision label, v3.5.5, replacing the previous v3.5.4, indicating an underlying platform update.SummaryDifference0.1%

Stay in the know with updates to GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GSK2636771 Combo with Pembrolizumab in Melanoma Clinical Trial page.